Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.

Overview of attention for article published in NEJM Evidence, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog
twitter: 82 X users

video: 1 YouTube creator
guideline: 1 clinical guideline source

Readers on

mendeley: 19 Mendeley

So far, Altmetric has seen 6 news stories from 5 outlets.

Opinion | Ending Oncology's Toxic Relationship With High Chemotherapy Doses

MedPage Today, 10 May 2024

Perspectives > Second Opinions Optimizing doses can improve patient outcomes and lower costs May 10, 2024 Sekeres is a leukemia…

New optimism on myelodysplastic syndromes

MedicalXpress, 02 Nov 2022

Credit: Pixabay/CC0 Public Domain Physician scientists at Sylvester Comprehensive Cancer Center at the University of Miami…

New review elucidates current treatment approaches for myelodysplastic syndromes

The Medical News, 02 Nov 2022

Physician scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have…

New Optimism on Myelodysplastic Syndromes

Sciencenewsnet.in, 01 Nov 2022

Post Views: 3 Physician scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.